[Skip to Content]
[Skip to Content Landing]

Precision Medicine For Your Practice: Prenatal Cell-Free DNA Screening

Learning Objectives
1. Determine if cell-free DNA screening is a good fit for the patient
2. Interpret results of cell-free DNA screening in the context of the patient characteristics
0.5 Credit CME

Precision Medicine for Your Practice is a series of short (approximately 30 min), online modules covering specific topics in genomics and precision medicine. In this module, Prenatal Cell-free DNA Screening, participants will learn about the benefits and limitations of cell-free DNA screening in prenatal care. Prenatal providers and patients have more options than ever for screening for Down syndrome and other chromosome conditions, including cell-free DNA screening. While cell-free DNA screening, also called noninvasive prenatal testing, is a powerful tool, it is not the best test for all pregnant people. Learn about specific benefits, limitations, and challenges in results interpretation and counseling using the five parts of this module: overview information via an animated video; practice cases to facilitate learning-by-doing; “dig deeper” activities; logistics; and additional resources for more detail.

Sign in to take quiz and track your certificates

Clinical Education from The Jackson Laboratory

Clinical Education from The Jackson Laboratory, developed in collaboration with Scripps Health and the AMA, empowers physicians and health care professionals to integrate genomics into their clinical practice. Learn more

Module not playing? Click here

Activity Information

Credit Designation Statement: The American Medical Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships.

If applicable, all relevant financial relationships have been mitigated.

Credit Renewal Dates: August 22, 2019, August 21, 2022

Disclosure Statement: In order to assure the highest quality of certified CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty, planners and members of the AMA CME Program Committee disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. The following disclosures are provided:

• Siobhan Dolan, MD, MPH, Stockholder of Sequenom

• Jeanette McCarthy, PhD, MPH, Consultant to Big Science Media, Omicia, and Precision Medicine Advisors

• Colleen Schmitt, MS, CGC, Employee of Counsyl, Inc.

• Suzanna Schott, ScM, CGC, Stockholder of Merck, Amgen, and Teva

• Janet K. Williams, PhD, RN, FAAN, Stockholder of Pfizer

No other planners or faculty have relevant financial relationships to disclose.

Accreditation Statement: The AMA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement: The AMA designates this Enduring Material activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Name Your Search

Save Search

Lookup An Activity


My Saved Searches

You currently have no searches saved.


My Saved Courses

You currently have no courses saved.